You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Predictors of lack of a diagnosis of prostate cancer in the SEER tumor registries among incident GnRH agonist users

From: Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

    Model 1a Model 2b
Variable Category Distribution (%) Odds Ratio 95% CI Odds Ratio 95% CI
Year of diagnosis 1993 11.5 1.00   1.00  
  1994 11.8 1.35 (0.59,3.10) 1.34 (0.58,3.09)
  1995 11.6 0.88 (0.35,2.19) 0.88 (0.35,2.20)
  1996 13.6 1.13 (0.49,2.61) 1.14 (0.49,2.65)
  1997 15.5 0.78 (0.33,1.88) 0.81 (0.34,1.95)
  1998 16.9 0.85 (0.37,1.98) 0.89 (0.38,2.07)
  1999 19.2 0.91 (0.41,2.04) 0.96 (0.43,2.17)
Age at diagnosis (years) 67 – 74 46.3 1.00   1.00  
  ≥75 53.7 1.38 (0.89,2.15) 1.24 (0.79,1.95)
Ethnicity White 83.0 1.00   1.00  
  Black 9.6 1.30 (0.66,2.58) 1.23 (0.62,2.46)
  Other 7.4 0.67 (0.27,1.65) 0.68 (0.28,1.68)
Region West 46.3 1.00   1.00  
  Northeast 14.8 0.86 (0.46,1.60) 0.84 (0.45,1.57)
  Midwest 31.1 0.51 (0.29,0.91) 0.46 (0.26,0.83)
  South 7.8 0.78 (0.36,1.71) 0.79 (0.36,1.72)
Comorbidity Index 0 71.4 1.00   1.00  
  ≥1 28.6 1.60 (1.03,2.48) 1.55 (1.00,2.41)
Zip education < 12.5% 25.7 1.00   1.00  
(% adult < 12 years education) ≥12.5% 74.3 1.24 (0.68,2.28) 1.24 (0.68,2.26)
Procedures within 3 months before or after diagnosis       
Hospitalization   21.2    1.48 (0.79,2.79)
Transurethral resection of prostate   8.4    0.19 (0.05,0.68)
Prostate Biopsy   77.9    0.59 (0.33,1.06)
Transrectal Ultrasound   58.7    0.96 (0.57,1.62)
Radical Prostatectomy   4.5    0.51 (0.13,2.00)
Radiation Therapy   17.1    0.27 (0.10,0.72)
CT scan/MRI pelvis   36.3    1.08 (0.63,1.85)
Bone scan   62.6    0.86 (0.52,1.44)
  1. aMultivariable logistic regression model with presence or absence of a diagnosis of prostate cancer in SEER as the dependent variable, and year of diagnosis, patient age, race, SEER region of residence, comorbidity index, and educational status entered as independent variables
  2. bMultivariable logistic regression model with presence or absence of a diagnosis of prostate cancer in SEER as the dependent variable, and the variables from Model 1 with the addition of the listed diagnostic procedures entered as independent variables
  3. GnRH; Gonadotropin-releasing hormone
  4. SEER; Surveillance, Epidemiology and End-Results